PharmaEssentia Announces Pipeline Presentation During Upcoming American Society of Hematology Annual Meeting

Company will update on its trial of ropeginterferon alfa-2b for essential thrombocythemia, which continues to enroll in the United States and Asia, and expands into Canada BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia Corporation (TPEx: 6446), a ...

Full "IntellAsia: Resources" article